期刊文献+

术前单疗程化疗对非小细胞肺癌细胞凋亡的影响 被引量:1

The effect of 1 cycle preoperative chemotherapy on NSCLC cell apoptosis
原文传递
导出
摘要 目的探讨术前单疗程化疗对ⅢA期非小细胞肺癌细胞凋亡率、增殖指数及bcl-2、bax基因表达的影响。方法 2002年1月至2004年1月,对144例ⅢA期非小细胞肺癌进行随机对照试验,术前化疗组(试验组)和单纯手术组(对照组)各72例,前者于术前化疗1个疗程,化疗结束10-14 d后接受手术;对照组直接行手术治疗。手术切除的肺癌组织应用流氏细胞学方法测定细胞凋亡率、增殖指数及bcl-2、bax基因的表达。结果试验组和对照组细胞凋亡率、增殖指数及bcl-2、bax基因表达分别为(7.40±2.39%)、(4.93±2.13)%;(24.99±7.51)%、(31.72±7.43)%;4.70±1.16、6.51±1.09;5.57±0.96、4.65±0.91,两组比较均差异有显著性(P〈0.05)。结论术前单疗程化疗能提高ⅢA期NSCLC的肿瘤细胞凋亡率,降低肿瘤细胞增殖指数,并抑制bcl-2基因(抑制凋亡的基因)的表达,促进bax基因(促进凋亡的基因)的表达,并可能降低细胞生存能力,减少癌转移灶的发生。 Objective To investigate the effect of one-cycle preoperative chemotherapy on apoptosis of stage-ⅢA non-small cell lung cancer cells and expression of bcl-2/bax gene.Methods From Jan 2002 to Jan 2004,144 patients were randomly divided into group A(preoperative chemotherapy group)and group B(control group,without preoperative chemotherapy).The patients in group A were given 1 cycle preoperative chemotherapy,and operations were performed in 10 to 14 days after chemotherapy.The patients in group B were only operated.Apoptotic index(AI),proliferation index(PI)and bcl-2/bax gene expression were detected with flow cytometry method.Results Apoptosis index(AI),proliferation index(PI),bcl-2 and bax expression of group A were(7.40±2.39)%,(24.99±7.51)%,4.70±1.16,5.57±0.96.Apoptosis index(AI),proliferation index(PI),bcl-2 and bax expression of group B were(4.93±2.13)%,(31.72±7.43)%,6.51±1.09,4.65±0.91.There were significant differences between the two groups.Conclusion The results demonstrate that the one-cycle preoperative chemotherapy could promote apoptosis decrease PI,inhibit Bcl-2 gene expression,promote bax gene expression decrease the viability of stage-ⅢA NSCLC cells,and may decrease metastasis.
出处 《中国肿瘤临床与康复》 2011年第1期28-30,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 肺肿瘤 术前化疗 细胞凋亡率 增殖指数 bcl-2 BAX Lung neoplasms Preoperative chemotherapy Apoptotic index Proliferation index Bcl-2 Bax
  • 相关文献

参考文献10

二级参考文献64

  • 1任占平,郑绍光,陈尉麟.应用SP免疫组化染色法的体会[J].诊断病理学杂志,1994,1(3):176-176. 被引量:69
  • 2[1]Albain KS, Pass HI. Induction therapy before surgery for non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶168-171.
  • 3[2]Saito Y, Minami K, Kobayashi M, et al. Ten year's experience of induction therapy for locally advanced NSCLC: a single institute study. Lung Cancer,2000,29(Suppl 1)∶89.
  • 4[3]De Pierre A, Milleron B, Chevret S, et al. French phase Ⅲ trial of preoperative chemotherapy (PCT) in resectable stage Ⅰ( except T1N0), Ⅱ,ⅢA non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶91.
  • 5[4]Pitz C, Riviere BDI, Beek FV, et al. Phase Ⅱ study of induction chemotherapy in patients with stage ⅢB NSCLC. Lung Cancer, 2000,29(Suppl 1)∶89.
  • 6[5]Abolhoda A, Martin J, Ginsberg RJ, et al. Morbidity and mortality for pulmonary resections in lung cancer after induction treatment. Lung Cancer,2000,29(Suppl 1)∶89.
  • 7[6]Mattson K, Velde T, Krofta K, et al. Early results of an international phase Ⅲ study evaluating Taxotere as neoadjuvant therapy for radically-treatable stage Ⅲ NSCLC. Lung Cancer,2000,29(Suppl 1)∶90.
  • 8[7]Kim J, Shim YM, Kim K, et al. A Phase Ⅱ trial of preoperative concurrent chemoradiotherapy for stage ⅢA non-small cell lung cancer with mediastinal lymph node involvement. Lung Cancer, 2000,29(Suppl 1)∶91.
  • 9[8]Date H, Kiura K, Aoe M, et al. Surgical resection of non-small cell lung cancer with mediastinal lymph node metastases after induction chemotherapy with cisplatin and irinotecan. Lung Cancer, 2000,29(Suppl 1)∶91.
  • 10[9]Betticher DC, Hsu SF, Gauthier Y, et al. Neoadjuvant therapy with Docetaxel (TAX) and cisplatin (Cis) in patients (pts) with non-small cell lung cancer (NSCLC), stage ⅢA, N2 is highly activity with few toxicities. Lung Cancer,2000,29(Suppl 1)∶99.

共引文献21

同被引文献7

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部